Article Text

AB0436 Do Patients Diagnosed with Chronic Inflammatory Arthropathies Treated with Rituximab Need Retreatment with the Same Dosage in Posterior Cycles? Analysis of the Sustained Response after Retreatment at A Lower Dose
  1. M.V. Hernández,
  2. A. Cuervo,
  3. V. Ruiz-Esquide,
  4. J. Ramírez,
  5. S. Cabrera-Villalba,
  6. J. Inciarte-Mundo,
  7. J.D.D. Cañete,
  8. R. Sanmartí
  1. Arthritis Unit. Rheumatology Department, Hospital Cliníc, Barcelona, Spain


Background The dosage of rituximab (RTX) approved for the treatment of active rheumatoid arthritis (RA) is two intravenous (iv.) 1 g infusions, separated by two weeks. However, it has recently been reported that, after initial treatment with the standard dosage, RTX retreatment at a lower dose may have comparable efficacy and be more cost-effective1

Objectives To analyse whether retreatment with RTX at a lower dose (1 g total dose) is equally effective in maintaining the clinical response as the standard dosage of cycles of 2g

Methods Observational, descriptive, retrospective study. We analysed the long-term efficacy of RTX retreatment with 1 g (total dose) cycles (2 iv. 500 mg infusions separated by 2 weeks; or 1 g iv single infusion) in routine clinical practise. All patients had initially been treated with at least one 2g (total dose) cycle, with a good response according to clinical judgment. The main efficacy variables were: mean DAS-28 score at the last follow-up visit and at the follow-up visit previous to RTX dose reduction; need to increase the RTX dose to the standard 2g dose; treatment withdrawal due to inefficacy. Secondary variables were: erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) values after retreatment in order to analyse variations between the last follow-up visit (dosage of 1g total dose) and the follow-up visit previous to RTX dose reduction (2g total dose).

Results From 2006 to 2013, 53 patients (86.8% RA) attended by our Department received at least, one cycle of 2g RTX (standard dosage); 41 out of 53 (77.3%) had a good response. Since September 2011, RTX retreatment was administered at a reduced 1g (total dose)/cycle in 29 patients (mean age: 59.5±10.4 years; 86.2% female; disease duration 11.7±7.9 years; 79.3% positive for rheumatoid factor/anti-cyclic citrullinated peptides). 79.3% of patients received concomitant disease-modifying antirheumatic drugs (DMARD) and 86.2% glucocorticoids. The mean number of RTX cycles received per patient before RTX dose reduction was 2.03±1.35. No increase in the DAS-28 score was found at the last follow-up visit (2.85±0.98) compared to the follow-up visit previous to RTX dose reduction (3.66±1.17) (p<0.0001). After a follow-up of 20.7±9.3 months, none of the 29 patients required a RTX dose increase or treatment withdrawal due to loss of efficacy. No significant differences were observed in ESR and CRP values between the last follow-up visit and the follow-up visit previous to the RTX dose reduction (mean ESR: 18.1±12.3 vs 18.4±13.1 mm/h, respectively; p=0.50; mean CRP: 0.6±0.8 vs 0.9±1.2 mg/dl, respectively; p=0.07). We observed no increase in the frequency of RTX cycles required after dose reduction (8.5±3.2 (1g total dose) vs 8.2±2.8 (2g total dose) months).

Conclusions After an initial favourable response to the standard dose of RTX, posterior retreatment with a total dose of 1g/cycle maintained the clinical response over time and was more cost-effective


  1. Mariette X et al. Ann Rheum Dis. 2013 May 30

Disclosure of Interest None declared

DOI 10.1136/annrheumdis-2014-eular.3535

Statistics from

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.